ReviewCancers2026
Integrative Profiling of Tumor and Blood Microenvironments to Uncover Molecular and Immune Determinants of Prognosis and Treatment Efficacy in Metastatic Colorectal Cancer.
Review in Cancers, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Metastatic colorectal cancer remains associated with poor prognosis despite major therapeutic advances, highlighting the need for robust biomarkers to refine treatment selection and monitor disease dynamics. This review summarizes emerging predictive and prognostic biomarkers in metastatic colorectal cancer across molecular and cellular layers, encompassing both tissue and circulating biomarkers. At the tissue level, we discuss genomic alterations and mutational signatures, transcriptomic classification systems and immune-related gene expression tools, protein-level immune checkpoint markers, and cellular determinants including immune infiltrates, cancer-associated fibroblasts and microbiome features. At the circulating level, we review biomarkers derived from liquid biopsy and peripheral blood, including circulating tumor DNA kinetics, T-cell receptor repertoire diversity, soluble cytokines and proteins, immune cell phenotyping, and circulating tumor cells. We highlight major challenges limiting clinical translation, including tumor heterogeneity, methodological variability, and the absence of standardized analytical pipelines and thresholds. Finally, we discuss future perspectives, emphasizing the integration of multi-omics biomarkers and artificial intelligence-driven strategies to improve biomarker validation and enable more precise management of metastatic colorectal cancer, particularly for patients with microsatellite-stable tumors who derive limited benefit from immune checkpoint inhibition.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.